rosiglitazone maleate

Also found in: Dictionary.

rosiglitazone maleate


Pharmacologic class: Thiazolidinedione

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia.


Tablets: 2 mg, 4 mg, 8 mg

Indications and dosages

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are either already taking rosiglitazone or not already taking rosiglitazone and are unable to achieve adequate glycemic control on other antidiabetics and, in consultation with their healthcare provider, have decided not to take pioglitazone for medical reasons

Adults: 4 mg P.O. once daily or 2 mg b.i.d. After 8 to 12 weeks, may increase to 8 mg daily or 4 mg b.i.d. if needed.

Off-label uses

• Polycystic ovary syndrome


• Established New York Heart Association (NYHA) Class III or IV heart failure


Use cautiously in:

• diabetic ketoacidosis, type 1 (insulin-dependent) diabetes mellitus (use not recommended)

• edema, NYHA Class I and II heart failure, elevated liver enzymes, jaundice

• concurrent use of insulin (not recommended)

• pregnant patients

• breastfeeding patients (use not recommended)

• children (safety and efficacy not established).


Obtain liver enzyme results before starting drug. Be aware that therapy shouldn't be initiated in patient with elevated baseline liver enzyme levels (alanine aminotransferase [ALT] level greater than 2.5 times the upper limit of normal) or if patient exhibits clinical evidence of active liver disease.

• Give with or without food.

• Be aware that drug is active only in presence of endogenous insulin and thus is ineffective in diabetic ketoacidosis or type 1 diabetes mellitus.

Adverse reactions

CNS: fatigue, headache

CV: hypertension, heart failure, increased risk of myocardial infarction

EENT: macular edema, decreased visual acuity, nasopharyngitis

GI: diarrhea

GU: menstrual dysfunction

Hematologic: anemia

Metabolic: hyperglycemia, hypoglycemia

Musculoskeletal: back pain, arthralgia, increased risk of fracture

Respiratory: upper respiratory infection

Other: edema, injury, weight gain


Drug-drug. CYP2C8 inducers (such as rifampin): decreased rosiglitazone area under the curve (AUC)

CYP2C8 inhibitors (such as gemfibrozil): increased rosiglitazone AUC

Drug-diagnostic tests. Free fatty acids, high-density lipoproteins, liver enzymes, low-density lipoproteins, total cholesterol: increased levels

Hematocrit, hemoglobin: decreased levels

Patient monitoring

• Monitor CBC, lipid panel, blood glucose, and glycosylated hemoglobin levels.

• Monitor patient's weight. Assess for fluid retention, which may lead to heart failure. Be aware that dosage increases should be accompanied by careful monitoring for adverse reactions related to fluid retention.

Closely monitor liver function tests. Be aware that patients with mildly elevated liver enzymes (ALT level 2.5 times ULN) at baseline or during therapy should be evaluated to determine cause of the liver enzyme elevation and if liver enzyme elevation resolves or worsens. If at any time ALT level increases to more than 3 times ULN, recheck liver enzyme levels as soon as possible. If ALT level remains at 3 times ULN, discontinue drug. If jaundice occurs, discontinue drug.

Patient teaching

• Tell patient he may take with or without food.

• Advise patient to monitor blood glucose level regularly and report significant changes.

Inform patient that drug may increase fluid retention, causing or exacerbating heart failure. Encourage him to weigh himself regularly and report sudden weight gain, swelling, or shortness of breath.

Teach patient to recognize and immediately report signs and symptoms of heart attack or liver problems.

• Tell patient to promptly report vision changes.

• Tell patient he'll undergo regular blood testing during therapy.

• Advise female patient that drug may result in ovulation in some premenopausal anovulatory women. Inform patient she may be at increased risk for pregnancy while taking this drug; recommend adequate contraception.

• Caution female patient not to breastfeed during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
Diclofenac Sodium + Misoprostol (Arthrotec 50) 50 mg/200 mcg tablet; Cetirizine 2HCl (Cetrizin) 10 mg tablet; Clindamycin (Clindacap300) 300 mg tablet; Simvastatin (Zimmex 20) 20 mg tablet; Rosiglitazone maleate (Avandia) 4 mg tablet; Gentamicin sulfate (Gentaderm) 0.1 g/ 100 g cream;
For example, drug safety concerns with Glaxo-SmithKline PLC's antidiabetes medication Avandia (rosiglitazone maleate) were widely reported by the media last year.
The subjects continued taking their usual doses of metformin throughout the study, but the other oral agent was with-drawn during an 8-week period prior to randomization to either rosiglitazone maleate or glyburide.
The subjects continued taking their usual doses of metformin throughout the study, but the other oral agent was withdrawn during an 8-week period prior to randomization to either rosiglitazone maleate or glyburide.
PHILADELPHIA -- GlaxoSmithKline PLC (GSK) announced that it has changed the product label for Avandia (rosiglitazone maleate), based on an extensive review by the Food and Drug Administration of myocardial ischemia data on the drug, which is used to treat type 2 diabetes.
Antidiabetes drugs rosiglitazone maleate (Avandia) and pioglitazone (Actos) have been found to increase adiponectin levels.
GSK asserts that the conclusions about the drug, also known as rosiglitazone maleate, are based "on incomplete evidence and a methodology that the author admits has significant limitations."
At a meeting, the Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee recommended FDA approval of rosiglitazone maleate for use as monotherapy and in combination with metformin in the treatment of type 2 diabetes.
PHILADELPHIA--The Food and Drug Administration has approved Avandia (rosiglitazone maleate) for use in combination with insulin for treating Type 2 diabetes.
The designation comes less than a year after the drug, known by its generic name of rosiglitazone maleate, won clearance from the regulatory agency for treating the same type of diabetes as both monotherapy and in combination with metformin as an adjunct to diet and exercise.